A team of researchers affiliated with Johns Hopkins University and Memorial Sloan Kettering Cancer Center has found some of the reasons for different responses to anti-PD-1 checkpoint blockade immunotherapy in cancer patients. ...
Immunotherapy for cancer has made great advances and many patients can now receive effective treatments that were not available 10 years ago. However, there are certain types of cancer that do not respond to existing immunotherapy. ...
Nov 23, 2020
0
87
A new approach to cancer therapy shows potential to transform the commonly used chemotherapy drug gemcitabine into a drug that kills cancer cells in a specialized way, activating immune cells to fight the cancer, according ...
Dec 7, 2020
0
339
During a battle with cancer, T cells can become exhausted and are no longer able to function properly. The early phase of exhaustion can sometimes be reversed with immunotherapy drugs, but once T cells become too exhausted, ...
Aug 5, 2022
0
501
Over the last decade, immunotherapy has emerged as one of the most promising and innovative fields in oncology. The goal of immunotherapy is to help a patient's own immune system fight cancer. A major breakthrough came in ...
Oct 18, 2017
0
4
A new study has identified a drug that potentially could make a common type of immunotherapy for cancer even more effective. The study in laboratory mice found that the drug dasatinib, which is FDA-approved to treat certain ...
Feb 20, 2019
0
423
DNA sequences from tumor cells can be used to direct the immune system to attack cancer, according to scientists at Washington University School of Medicine in St. Louis.
Feb 8, 2012
1
0
Though cancer immunotherapy has become a promising standard-of-care treatment—and in some cases, perhaps a cure—for a wide variety of different cancers, it doesn't work for everyone, and researchers have increasingly ...
Oct 2, 2020
0
95
An urgent question for cancer scientists is why immunotherapy achieves dramatic results in some cases but doesn't help most patients. Now, two research groups from Dana-Farber Cancer Institute have independently discovered ...
Jan 4, 2018
1
149
A UCLA-led study suggests that for people with recurrent glioblastoma, administering an immunotherapy drug before surgery is more effective than using the drug afterward.
Feb 11, 2019
0
199
